AB Science S.A. (ABSCF)

Market Cap	126.13M
Revenue (ttm)	1.11M
Net Income (ttm)	-8.11M
Shares Out	n/a
EPS (ttm)	-0.16
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	400
Average Volume	8,476
Open	1.260
Previous Close	1.600
Day's Range	1.260 - 1.260
52-Week Range	0.800 - 1.600
Beta	1.58
RSI	30.41
Earnings Date	Sep 30, 2025

About AB Science

AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company’s lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer’s disease, ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 39
• Stock Exchange: OTCMKTS
• Ticker Symbol: ABSCF

Financial Performance

In 2024, AB Science's revenue was 1.07 million, an increase of 10.52% compared to the previous year's 970,000. Losses were -7.83 million, -34.66% less than in 2023.

Financial numbers in EUR